Cargando…
Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia
HPV immunization programs are mainly focused on girls and boys, but adult women and men could also benefit from vaccination. A multinational CoheaHr-WP4 study investigated the acceptability of HPV vaccination among 25–45 years old women. A total of 607 women from Slovenia participated in the study,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964155/ https://www.ncbi.nlm.nih.gov/pubmed/36851300 http://dx.doi.org/10.3390/vaccines11020423 |
_version_ | 1784896432638001152 |
---|---|
author | Mlakar, Jana Oštrbenk Valenčak, Anja Kežar, Jožefa Beseničar-Pregelj, Lara Poljak, Mario |
author_facet | Mlakar, Jana Oštrbenk Valenčak, Anja Kežar, Jožefa Beseničar-Pregelj, Lara Poljak, Mario |
author_sort | Mlakar, Jana |
collection | PubMed |
description | HPV immunization programs are mainly focused on girls and boys, but adult women and men could also benefit from vaccination. A multinational CoheaHr-WP4 study investigated the acceptability of HPV vaccination among 25–45 years old women. A total of 607 women from Slovenia participated in the study, and 49.6% (301/607) agreed with HPV vaccination, with a significant difference (p < 0.0001) between the two centers. Non-vaccinated women had a higher education (p = 0.0068) and were more frequently in a committed relationship or married (p = 0.01). The most trusted source of medical and vaccination information was healthcare providers (55.2%). The main reasons for vaccine acceptance were protection against HPV-related disease (93.4%), severity of preventable diseases (82.7%), HPV vaccine safety (66.8%), free HPV vaccine availability (62.8%), and the existence of vaccination recommendations (55.5%). The main reasons for refusing vaccination were the need for additional vaccine-related information (31.4%) and vaccine safety concerns (29.4%). To increase vaccine coverage, information about the benefits and safety of HPV vaccination must be widely disseminated to all health professionals and the general public. We are convinced that the knowledge obtained in this study can be reliably applied to other countries in the region that lack such information and have a very high cervical cancer burden. |
format | Online Article Text |
id | pubmed-9964155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99641552023-02-26 Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia Mlakar, Jana Oštrbenk Valenčak, Anja Kežar, Jožefa Beseničar-Pregelj, Lara Poljak, Mario Vaccines (Basel) Article HPV immunization programs are mainly focused on girls and boys, but adult women and men could also benefit from vaccination. A multinational CoheaHr-WP4 study investigated the acceptability of HPV vaccination among 25–45 years old women. A total of 607 women from Slovenia participated in the study, and 49.6% (301/607) agreed with HPV vaccination, with a significant difference (p < 0.0001) between the two centers. Non-vaccinated women had a higher education (p = 0.0068) and were more frequently in a committed relationship or married (p = 0.01). The most trusted source of medical and vaccination information was healthcare providers (55.2%). The main reasons for vaccine acceptance were protection against HPV-related disease (93.4%), severity of preventable diseases (82.7%), HPV vaccine safety (66.8%), free HPV vaccine availability (62.8%), and the existence of vaccination recommendations (55.5%). The main reasons for refusing vaccination were the need for additional vaccine-related information (31.4%) and vaccine safety concerns (29.4%). To increase vaccine coverage, information about the benefits and safety of HPV vaccination must be widely disseminated to all health professionals and the general public. We are convinced that the knowledge obtained in this study can be reliably applied to other countries in the region that lack such information and have a very high cervical cancer burden. MDPI 2023-02-12 /pmc/articles/PMC9964155/ /pubmed/36851300 http://dx.doi.org/10.3390/vaccines11020423 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mlakar, Jana Oštrbenk Valenčak, Anja Kežar, Jožefa Beseničar-Pregelj, Lara Poljak, Mario Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia |
title | Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia |
title_full | Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia |
title_fullStr | Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia |
title_full_unstemmed | Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia |
title_short | Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia |
title_sort | assessment of acceptability and determinants of uptake and schedule completion of human papillomavirus (hpv) vaccine by 25 to 45 years old women in slovenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964155/ https://www.ncbi.nlm.nih.gov/pubmed/36851300 http://dx.doi.org/10.3390/vaccines11020423 |
work_keys_str_mv | AT mlakarjana assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia AT ostrbenkvalencakanja assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia AT kezarjozefa assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia AT besenicarpregeljlara assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia AT poljakmario assessmentofacceptabilityanddeterminantsofuptakeandschedulecompletionofhumanpapillomavirushpvvaccineby25to45yearsoldwomeninslovenia |